Cost–effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK

Rositsa Koleva-Kolarova*, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen van Molken, László Szilberhorn, Tamás Zelei, Balázs Nagy, Sarah Wordsworth, Apostolos Tsiachristas

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
11 Downloads (Pure)


The aim of this study was to evaluate the cost–effectiveness of ToxNavC , a multivariant genetic test, to screen for DPYD followed by personalized chemotherapy dosing for metastatic breast cancer in the UK compared with no testing followed by standard dose, standard of care. In the main analysis, ToxNav was dominant over standard of care, producing 0.19 additional quality-adjusted life years and savings of £78,000 per patient over a lifetime. The mean additional quality-adjusted life years per person from 1000 simulations was 0.23 savings (95% CI: 0.22–0.24) at £99,000 (95% CI: £95–102,000). Varying input parameters independently by range of 20% was unlikely to change the results in the main analysis. The probabilistic sensitivity analysis showed ∼97% probability of the ToxNav strategy to be dominant.
Original languageEnglish
Pages (from-to)339-355
Number of pages18
JournalPersonalized Medicine
Issue number4
Publication statusPublished - 1 Jul 2023

Bibliographical note

Funding information:
The HEcoPerMed project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 824997. S Wordsworth is a co-applicant of a project funded through Genome British Columbia’s GeneSolve program and Illumina and has received travel support from Illumina to attend conferences in MD, USA; Barcelona, Spain; and Basel, Switzerland. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

2023 The Authors


Dive into the research topics of 'Cost–effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK'. Together they form a unique fingerprint.

Cite this